AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 25961781 — intervention group
Group type: EXPERIMENTAL
Intervention: BMS-820836 flexible dose (0.5-2 mg/d)
Number of subjects: 0
Study 25961781 — intervention group
Group type: EXPERIMENTAL
Intervention: BMS-820836 fixed dose (1 mg/d or greater)
Number of subjects: 0
Study 25961781 — intervention group
Group type: COMPARATOR
Intervention: Continuation of duloxetine (60 mg/d)
Number of subjects: 0
Study 25961781 — intervention group
Group type: EXPERIMENTAL
Intervention: BMS-820836 (1 mg/d)
Number of subjects: 0
Study 25961781 — intervention group
Group type: EXPERIMENTAL
Intervention: BMS-820836 (2 mg/d)
Number of subjects: 0
Study 25961781 — intervention group
Group type: COMPARATOR
Intervention: Continuation group
Number of subjects: 0
Study 23139259 — intervention group
Group type: EXPERIMENTAL
Intervention: P + CRT
Number of subjects: 68
Study 23139259 — intervention group
Group type: COMPARATOR
Intervention: CRT
Number of subjects: 68
Study 21764215 — intervention group
Group type: EXPERIMENTAL
Intervention: Active TMS (4000 pulses at 10 Hz for 10 sessions over 2 weeks)
Number of subjects: 20
Study 21764215 — intervention group
Group type: COMPARATOR
Intervention: Sham TMS
Number of subjects: 20
Study 21764215 — intervention group
Group type: EXPERIMENTAL
Intervention: Active TMS
Number of subjects: 20
Study 19298914 — intervention group
Group type: EXPERIMENTAL
Intervention: Bivalirudin alone
Number of subjects: 13819
Study 19298914 — intervention group
Group type: COMPARATOR
Intervention: Heparin and glycoprotein IIb/IIIa inhibitors
Number of subjects: 13819
Study 17668529 — intervention group
Group type: EXPERIMENTAL
Intervention: Adapalene gel 0.3%
Number of subjects: 0
Study 17668529 — intervention group
Group type: COMPARATOR
Intervention: Tazarotene cream 0.05%
Number of subjects: 0
Study 15500492 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketamine
Number of subjects: 706
Study 15500492 — intervention group
Group type: COMPARATOR
Intervention: Extra midazolam
Number of subjects: 706
Study 15500492 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 706
Study 11749817 — intervention group
Group type: EXPERIMENTAL
Intervention: Huangqi Jianzhong Tang (HQJZT)
Number of subjects: 24
Study 11749817 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 9635328 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental group (amount of practice received)
Number of subjects: 83
Study 9635328 — intervention group
Group type: COMPARATOR
Intervention: Control group (amount of practice received)
Number of subjects: 83
Study 9635328 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental group (alpha power increase)
Number of subjects: 83
Study 9635328 — intervention group
Group type: COMPARATOR
Intervention: Control group (alpha power increase)
Number of subjects: 83
Study 8049053 — intervention group
Group type: EXPERIMENTAL
Intervention: Laryngeal mask airway (LMA)
Number of subjects: 50
Study 8049053 — intervention group
Group type: COMPARATOR
Intervention: Face mask and Guedel oral airway (FM‐OA)
Number of subjects: 50
Study 3289675 — intervention group
Group type: EXPERIMENTAL
Intervention: terodiline 25 mg bd
Number of subjects: 20
Study 3289675 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 20
Study 3289675 — intervention group
Group type: EXPERIMENTAL
Intervention: emepronium bromide 200 mg tds
Number of subjects: 20
Study 31883255 — intervention group
Group type: EXPERIMENTAL
Intervention: 5% green tea mouthwash
Number of subjects: 64
Study 31883255 — intervention group
Group type: EXPERIMENTAL
Intervention: 20% green tea with xylitol mouthwash
Number of subjects: 64
Study 27998961 — intervention group
Group type: EXPERIMENTAL
Intervention: Trastuzumab alone followed by chemotherapy at disease progression (Arm A)
Number of subjects: 175
Study 27998961 — intervention group
Group type: COMPARATOR
Intervention: Upfront trastuzumab plus chemotherapy (Arm B)
Number of subjects: 175
Study 27998961 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients without visceral disease in Arm A
Number of subjects: 175
Study 27998961 — intervention group
Group type: COMPARATOR
Intervention: Patients without visceral disease in Arm B
Number of subjects: 175
Study 27998961 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall survival for both arms
Number of subjects: 175
Study 27998961 — intervention group
Group type: EXPERIMENTAL
Intervention: Toxicity
Number of subjects: 175
Study 25710507 — intervention group
Group type: EXPERIMENTAL
Intervention: CXL treatment (0.1% riboflavin drops and UV-A irradiation at 365 nm for 30 minutes)
Number of subjects: 32
Study 25710507 — intervention group
Group type: EXPERIMENTAL
Intervention: CXL treatment
Number of subjects: 32
Study 25710507 — intervention group
Group type: COMPARATOR
Intervention: Standard medical treatment (Control group)
Number of subjects: 32
Study 23525597 — intervention group
Group type: EXPERIMENTAL
Intervention: Stable light/occasional smokers
Number of subjects: 3521
Study 23525597 — intervention group
Group type: EXPERIMENTAL
Intervention: Accelerating smokers
Number of subjects: 3521
Study 23525597 — intervention group
Group type: COMPARATOR
Intervention: Nonsmokers
Number of subjects: 3521
Study 23525597 — intervention group
Group type: EXPERIMENTAL
Intervention: Stable light/occasional smokers and accelerating smokers
Number of subjects: 3521
Study 23525597 — intervention group
Group type: EXPERIMENTAL
Intervention: Accelerating smoking trajectory group
Number of subjects: 3521
Study 21345638 — intervention group
Group type: EXPERIMENTAL
Intervention: Filter-leukoreduced platelet transfusions
Number of subjects: 145
Study 21345638 — intervention group
Group type: EXPERIMENTAL
Intervention: UV-B-irradiated platelet transfusions
Number of subjects: 145
Study 21345638 — intervention group
Group type: COMPARATOR
Intervention: Standard platelet transfusions
Number of subjects: 145
Study 21345638 — intervention group
Group type: EXPERIMENTAL
Intervention: Antibody persistence evaluation
Number of subjects: 145
Study 21345638 — intervention group
Group type: EXPERIMENTAL
Intervention: Type of platelets transfused during the trial
Number of subjects: 145
Study 18679064 — intervention group
Group type: EXPERIMENTAL
Intervention: Granulocyte and monocyte/macrophage adsorptive apheresis (GMCAP)
Number of subjects: 39
Study 18679064 — intervention group
Group type: COMPARATOR
Intervention: Leukocytapheresis (LCAP)
Number of subjects: 39
Study 18679064 — intervention group
Group type: EXPERIMENTAL
Intervention: Both GMCAP and LCAP
Number of subjects: 39
Study 16441800 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg of dexamethasone
Number of subjects: 72
Study 16441800 — intervention group
Group type: COMPARATOR
Intervention: 2 mL of saline
Number of subjects: 72
Study 12680422 — intervention group
Group type: EXPERIMENTAL
Intervention: Alefacept
Number of subjects: 0
Study 12680422 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 10811673 — intervention group
Group type: EXPERIMENTAL
Intervention: Docetaxel 100 mg/m(2) given as a 1‐hour intravenous infusion every 3 weeks
Number of subjects: 86
Study 10811673 — intervention group
Group type: COMPARATOR
Intervention: Doxorubicin 75 mg/m(2) given as a bolus injection every 3 weeks
Number of subjects: 86
Study 8805964 — intervention group
Group type: EXPERIMENTAL
Intervention: Relaxation with Mucosal Immune Imagery (RI)
Number of subjects: 121
Study 8805964 — intervention group
Group type: EXPERIMENTAL
Intervention: Relaxation Alone (R)
Number of subjects: 121
Study 8805964 — intervention group
Group type: COMPARATOR
Intervention: Vigilance Task control (VT)
Number of subjects: 121
Study 1457907 — intervention group
Group type: EXPERIMENTAL
Intervention: Quinine 325 mg at bedtime
Number of subjects: 40
Study 1457907 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin E 400 IU at bedtime
Number of subjects: 40
Study 1457907 — intervention group
Group type: COMPARATOR
Intervention: Placebo washout (baseline)
Number of subjects: 40
Study 1457907 — intervention group
Group type: EXPERIMENTAL
Intervention: Severity of pain index
Number of subjects: 40
Study 6694348 — intervention group
Group type: EXPERIMENTAL
Intervention: 8 hours training per week
Number of subjects: 33
Study 6694348 — intervention group
Group type: COMPARATOR
Intervention: Control (3 1/2 hours training per week)
Number of subjects: 33
Study 31165869 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive behavior change interventions (IPC, AG, CM, MM)
Number of subjects: 2646
Study 28902105 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulsed Radiofrequency (PRF) stimulation
Number of subjects: 23
Study 28902105 — intervention group
Group type: COMPARATOR
Intervention: Intra-articular Corticosteroid Injection (ICI)
Number of subjects: 23
Study 27388828 — intervention group
Group type: EXPERIMENTAL
Intervention: Paclitaxel-based drug-eluting balloon (DEB) angioplasty (n = 35)
Number of subjects: 74
Study 27388828 — intervention group
Group type: COMPARATOR
Intervention: Standard percutaneous transluminal angioplasty (PTA) (n = 39)
Number of subjects: 74
Study 24935999 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine 1 mg/kg
Number of subjects: 202
Study 24935999 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine 2 mg/kg
Number of subjects: 202
Study 24935999 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 202
Study 24935999 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine (both doses)
Number of subjects: 202
Study 24935999 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine in post‐pubertal girls
Number of subjects: 202
Study 22511570 — intervention group
Group type: EXPERIMENTAL
Intervention: Work place ergonomic intervention
Number of subjects: 89
Study 22511570 — intervention group
Group type: COMPARATOR
Intervention: Control (provision of written educational materials)
Number of subjects: 89
Study 20613496 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of telmisartan (80 mg) and amlodipine (10 mg)
Number of subjects: 562
Study 20613496 — intervention group
Group type: COMPARATOR
Intervention: Amlodipine (10 mg)
Number of subjects: 562
Study 20613496 — intervention group
Group type: COMPARATOR
Intervention: Telmisartan (80 mg)
Number of subjects: 562
Study 20613496 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy
Number of subjects: 562
Study 18042475 — intervention group
Group type: EXPERIMENTAL
Intervention: Rosuvastatin 5 mg
Number of subjects: 12
Study 18042475 — intervention group
Group type: EXPERIMENTAL
Intervention: Rosuvastatin 10 mg
Number of subjects: 12
Study 18042475 — intervention group
Group type: EXPERIMENTAL
Intervention: Rosuvastatin 20 mg
Number of subjects: 12
Study 18042475 — intervention group
Group type: COMPARATOR
Intervention: Rosuvastatin 10 mg (fed state)
Number of subjects: 12
Study 15122133 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.2% ropivacaine PCA infusion at 5 mL per hour with a bolus dose of 2 mL at a 15-minute lockout period (group I)
Number of subjects: 24
Study 15122133 — intervention group
Group type: COMPARATOR
Intervention: Saline infusion under the same conditions (group II)
Number of subjects: 24
Study 12377962 — intervention group
Group type: EXPERIMENTAL
Intervention: Gemcitabine with cisplatin
Number of subjects: 175
Study 12377962 — intervention group
Group type: EXPERIMENTAL
Intervention: Paclitaxel with cisplatin
Number of subjects: 175
Study 12377962 — intervention group
Group type: EXPERIMENTAL
Intervention: Vinorelbine with cisplatin
Number of subjects: 175
Study 12377962 — intervention group
Group type: EXPERIMENTAL
Intervention: All arms (gemcitabine, paclitaxel, vinorelbine with cisplatin)
Number of subjects: 175
Study 9619811 — intervention group
Group type: EXPERIMENTAL
Intervention: Willingness to participate in a randomized vaccine efficacy trial
Number of subjects: 4892
Study 9619811 — intervention group
Group type: EXPERIMENTAL
Intervention: Factors influencing decision-making
Number of subjects: 4892
Study 9619811 — intervention group
Group type: EXPERIMENTAL
Intervention: Motivators for participation
Number of subjects: 4892
Study 9619811 — intervention group
Group type: EXPERIMENTAL
Intervention: Concerns regarding participation
Number of subjects: 4892
Study 9619811 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline knowledge of vaccine trial concepts
Number of subjects: 4892
Study 8087909 — intervention group
Group type: EXPERIMENTAL
Intervention: Sugarless gum chewing (Group 2)
Number of subjects: 77
Study 8087909 — intervention group
Group type: COMPARATOR
Intervention: Control group (Group 1)
Number of subjects: 77
Study 8087909 — intervention group
Group type: EXPERIMENTAL
Intervention: Sugarless gum chewing (Group 3)
Number of subjects: 77
Study 2781237 — intervention group
Group type: EXPERIMENTAL
Intervention: Erosive prepyloric changes (EPC) grade 2 or 3
Number of subjects: 60
Study 326495 — intervention group
Group type: EXPERIMENTAL
Intervention: Indapamide (2.5 mg to 5 mg)
Number of subjects: 10
Study 326495 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 31556099 — intervention group
Group type: EXPERIMENTAL
Intervention: Atopic dermatitis (AD) severity
Number of subjects: 3834
Study 31556099 — intervention group
Group type: EXPERIMENTAL
Intervention: Pain medication use in AD patients
Number of subjects: 3834
Study 31556099 — intervention group
Group type: EXPERIMENTAL
Intervention: Skin pain scores in AD patients
Number of subjects: 3834
Study 31556099 — intervention group
Group type: COMPARATOR
Intervention: Comparison of pain medication use
Number of subjects: 3834
Study 31092664 — intervention group
Group type: EXPERIMENTAL
Intervention: MyBackPain.org.au website access
Number of subjects: 440
Study 31092664 — intervention group
Group type: COMPARATOR
Intervention: Publicly available online information (control group)
Number of subjects: 440
Study 28068596 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin plus omega 3
Number of subjects: 80
Study 28068596 — intervention group
Group type: COMPARATOR
Intervention: Aspirin
Number of subjects: 80
Study 27260482 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrashort anatomic cementless stem
Number of subjects: 200
Study 27260482 — intervention group
Group type: COMPARATOR
Intervention: Conventional anatomic cementless stem
Number of subjects: 200
Study 24474088 — intervention group
Group type: EXPERIMENTAL
Intervention: Cemented femoral stem with polished finish and collar
Number of subjects: 163
Study 24474088 — intervention group
Group type: EXPERIMENTAL
Intervention: Cemented femoral stem with matt finish and collar
Number of subjects: 163
Study 24474088 — intervention group
Group type: EXPERIMENTAL
Intervention: Cemented femoral stem with polished finish and collarless
Number of subjects: 163
Study 24474088 — intervention group
Group type: EXPERIMENTAL
Intervention: Cemented femoral stem with matt finish and collarless
Number of subjects: 163
Study 24474088 — intervention group
Group type: COMPARATOR
Intervention: Cemented femoral stem with matt collarless
Number of subjects: 163
Study 24474088 — intervention group
Group type: COMPARATOR
Intervention: Cemented femoral stem with polished collarless
Number of subjects: 163
Study 21204889 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy with VCE supplementation (vitamin C 500 mg tablet and vitamin E 400 mg gelatin capsule)
Number of subjects: 40
Study 21204889 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy alone (5‐fluorouracil 500 mg/m(2) i.v. day 1, doxorubicin 50 mg/m(2) i.v. day 1, cyclophosphamide 500 mg/m(2) i.v. day 1, every 3 weeks for six cycles)
Number of subjects: 40
Study 19852273 — intervention group
Group type: COMPARATOR
Intervention: Terazosin
Number of subjects: 168
Study 19852273 — intervention group
Group type: COMPARATOR
Intervention: Chlormezanone
Number of subjects: 168
Study 19852273 — intervention group
Group type: EXPERIMENTAL
Intervention: Terazosin + Chlormezanone
Number of subjects: 168
Study 17445266 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 mg 5-ALA via inhalation 1, 2, 3, 4 or 6 hours before bronchoscopy
Number of subjects: 19
Study 17445266 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 mg 5-ALA via inhalation
Number of subjects: 19
Study 17445266 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 mg 5-ALA via inhalation 160 min prior to bronchoscopy
Number of subjects: 19
Study 15610951 — intervention group
Group type: EXPERIMENTAL
Intervention: High dose transdermal nicotine patch (14 or 21 mg)
Number of subjects: 85
Study 15610951 — intervention group
Group type: EXPERIMENTAL
Intervention: Low dose transdermal nicotine patch (7 mg)
Number of subjects: 85
Study 15610951 — intervention group
Group type: COMPARATOR
Intervention: Control group (no nicotine patch)
Number of subjects: 85
Study 12200355 — intervention group
Group type: EXPERIMENTAL
Intervention: Ursodeoxycholic acid (UDCA) 12 mg/kg/d orally from the day preceding conditioning until day 90 after transplantation
Number of subjects: 242
Study 12200355 — intervention group
Group type: COMPARATOR
Intervention: Control group (no UDCA)
Number of subjects: 242
Study 10443309 — intervention group
Group type: EXPERIMENTAL
Intervention: Arterial rigidity measurements
Number of subjects: 0
Study 10443309 — intervention group
Group type: COMPARATOR
Intervention: Framingham equation
Number of subjects: 0
Study 7579052 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-protein diet group
Number of subjects: 200
Study 7579052 — intervention group
Group type: EXPERIMENTAL
Intervention: Low blood pressure group
Number of subjects: 200
Study 7579052 — intervention group
Group type: EXPERIMENTAL
Intervention: Low MAP group
Number of subjects: 200
Study 7579052 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower protein intake
Number of subjects: 200
Study 7579052 — intervention group
Group type: EXPERIMENTAL
Intervention: Prescription of the keto acid‐amino acid supplement
Number of subjects: 200
Study 2357862 — intervention group
Group type: EXPERIMENTAL
Intervention: 400 mg caffeine plus 75 mg phenylpropanolamine
Number of subjects: 16
Study 2357862 — intervention group
Group type: COMPARATOR
Intervention: 400 mg caffeine alone
Number of subjects: 16
Study 2357862 — intervention group
Group type: EXPERIMENTAL
Intervention: phenylpropanolamine-caffeine combination
Number of subjects: 16
Study 6153904 — intervention group
Group type: EXPERIMENTAL
Intervention: argon laser photocoagulation
Number of subjects: 67
Study 6153904 — intervention group
Group type: EXPERIMENTAL
Intervention: xenon photocoagulation
Number of subjects: 67
Study 6153904 — intervention group
Group type: COMPARATOR
Intervention: Control (untreated eye)
Number of subjects: 67
Study 31004574 — intervention group
Group type: EXPERIMENTAL
Intervention: Fibrinogen concentrate
Number of subjects: 45
Study 31004574 — intervention group
Group type: EXPERIMENTAL
Intervention: TEG
Number of subjects: 45
Study 31004574 — intervention group
Group type: EXPERIMENTAL
Intervention: ROTEM
Number of subjects: 45
Study 31004574 — intervention group
Group type: COMPARATOR
Intervention: CCTs
Number of subjects: 45
Study 31004574 — intervention group
Group type: EXPERIMENTAL
Intervention: TEG and ROTEM
Number of subjects: 45
Study 28477398 — intervention group
Group type: EXPERIMENTAL
Intervention: One-to-one simulated patient (SP) training with individual feedback
Number of subjects: 236
Study 28477398 — intervention group
Group type: COMPARATOR
Intervention: Small-group SP training with collective feedback
Number of subjects: 236
Study 25589326 — intervention group
Group type: EXPERIMENTAL
Intervention: Albendazole plus oxantel pamoate (400 mg + 20 mg/kg)
Number of subjects: 440
Study 25589326 — intervention group
Group type: EXPERIMENTAL
Intervention: Albendazole plus ivermectin (400 mg + 200 μg/kg)
Number of subjects: 440
Study 25589326 — intervention group
Group type: COMPARATOR
Intervention: Mebendazole alone (500 mg)
Number of subjects: 440
Study 25589326 — intervention group
Group type: EXPERIMENTAL
Intervention: Albendazole plus mebendazole (400 mg + 500 mg)
Number of subjects: 440
Study 24495468 — intervention group
Group type: EXPERIMENTAL
Intervention: Melatonin 3 mg orally
Number of subjects: 78
Study 24495468 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 78
Study 22967344 — intervention group
Group type: EXPERIMENTAL
Intervention: Acarbose 50 mg added to insulin treatment
Number of subjects: 120
Study 22967344 — intervention group
Group type: COMPARATOR
Intervention: Preprandial ultra-short effect insulin and long-acting insulin before bedtime (Control group)
Number of subjects: 120
Study 19926783 — intervention group
Group type: EXPERIMENTAL
Intervention: 125 microg T(4)
Number of subjects: 21
Study 19926783 — intervention group
Group type: EXPERIMENTAL
Intervention: 250 microg T(4)
Number of subjects: 21
Study 19926783 — intervention group
Group type: EXPERIMENTAL
Intervention: 25 microg T(3)
Number of subjects: 21
Study 19926783 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 microg T(3)
Number of subjects: 21
Study 19926783 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21
Study 17986032 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral midazolam 0.5 mg.kg (‐1)
Number of subjects: 64
Study 17986032 — intervention group
Group type: COMPARATOR
Intervention: Oral clonidine 4 microg.kg (‐1)
Number of subjects: 64
Study 15945402 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D supplementation (400 IU daily)
Number of subjects: 51
Study 15945402 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 51
Study 12194554 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic adjustable gastric banding
Number of subjects: 52
Study 12194554 — intervention group
Group type: COMPARATOR
Intervention: Adjustable esophagogastric banding
Number of subjects: 52
Study 9456288 — intervention group
Group type: EXPERIMENTAL
Intervention: celiprolol (200-400 mg daily)
Number of subjects: 25
Study 7497033 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified Allen's test
Number of subjects: 74
Study 7497033 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulse oximetry
Number of subjects: 74
Study 7497033 — intervention group
Group type: EXPERIMENTAL
Intervention: Plethysmography
Number of subjects: 74
Study 7497033 — intervention group
Group type: EXPERIMENTAL
Intervention: Laser Doppler perfusion monitoring
Number of subjects: 74
Study 2119168 — intervention group
Group type: EXPERIMENTAL
Intervention: sorbinil (250 mg daily for 3 years)
Number of subjects: 497
Study 2119168 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 497
Study 2119168 — intervention group
Group type: EXPERIMENTAL
Intervention: sorbinil
Number of subjects: 497
Study 7435677 — intervention group
Group type: EXPERIMENTAL
Intervention: Amitriptyline alone, up to a maximum dose of 300 mg/day
Number of subjects: 30
Study 7435677 — intervention group
Group type: EXPERIMENTAL
Intervention: Tranylcypromine alone, up to a maximum dose of 40 mg/day
Number of subjects: 30
Study 7435677 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of amitriptyline (up to 150 mg/day) and tranylcypromine (up to 20 mg/day)
Number of subjects: 30
Study 30606469 — intervention group
Group type: EXPERIMENTAL
Intervention: ERAS program
Number of subjects: 180